Prevalence and Distribution of HPV Genotypes in 1387 Women with Cervical Intraepithelial Neoplasia 2/3 in Shanxi Province, China

Zhilian Wang1, Zaibo Li2, Jing Li1, Chen Wang1, Wenhao Wang1, Min Hao1, Chengquan Zhao3

1. Department of Obstetrics and Gynecology, Second Hospital of Shanxi Medical University, Taiyuan, China.
2. Department of Pathology, Ohio State Wexner Medical Center, Columbus, OH 43210, USA.
3. Department of Pathology, Magee-Womens Hospital, University of Pittsburgh Medical Center. 300 Halket St, Pittsburgh, PA, 15213, USA.

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Abstract

Objective: The distribution of human papillomavirus (HPV) genotypes varies by countries and regions. Data regarding HPV genotype distribution for women with cervical intraepithelial neoplasia 2/3 (CIN2/3) are still limited. This study aimed to investigate the distribution of HPV genotypes for women with CIN2/3 in Shanxi province, China.

Methods: Prior HPV testing/genotyping resulted from women with histologic diagnosis of CIN2/3 were retrospectively collected between August 2011 and August 2016.

Results: A total of 1387 women with a diagnosis of CIN2/3 were included in this study. The average age of the women was 45.7 years and the average time period from HPV testing to histological diagnosis was 0.4 months. The overall high-risk HPV (hrHPV) positive rate was 91.6%. In all tested women, the most commonly detected hrHPV genotype was HPV16 (59.3%) followed by HPV58 (14.4%) and HPV33 (10.0%), while HPV18 was in the 6th position (6.0%).

Conclusions: This is one of the largest studies of HPV genotyping for women with CIN2/3 in China. The prevalence and distribution of HPV genotypes in these Chinese women differed from those in women from Western countries. Our results provide important information for developing specific HPV vaccines for Chinese women.

Key words: HPV genotyping, Neoplasia 2/3, Prevalence

Introduction

Cervical cancer is the fourth most common cancer among women worldwide in terms of morbidity and mortality. More than 85% of cervical cancers occur in the developing countries.1 China accounts for 14% of the world’s annual incidence of cervical cancer, and hence it remains an important public health problem in China.2, 3 The incidence of cervical cancer in Shanxi Province, China is strikingly high.4 Persistent infection of high-risk Human Papillomavirus (hrHPV) infection is critical for the development of almost all cervical cancers and precancerous lesions.5 A meta-analysis of 48 studies showed that HPV16 and HPV18 are the most prevalent genotypes worldwide.6 It has been shown that the distribution of HPV genotypes in cervical cancers varies by countries and regions.7 China is a large country with varied socioeconomic conditions among different regions, and HPV infections differ accordingly.8 A large study from China, which included 51,345 women, has demonstrated three most common hrHPV types were HPV52, 16, and 58, while HPV18 was only the 6th most common type.9

HPV vaccination is one of the most important measures to prevent HPV infection.10 However, all
currently available vaccines were developed based on the epidemiological data from Western countries, and as a result, target HPV16, HPV18 and several other commonly identified subtypes in Western countries. Implementation of these vaccines in China may not be able to achieve the desired preventive efficacy. Therefore, in order to develop HPV vaccines specific for Chinese women, it is necessary to investigate HPV genotype distributions in China.

Materials and Methods

Study participants

The cases with histological diagnosis of CIN2/3 rendered between August 2011 and August 2016 were retrospectively searched in the patient information system at Second Hospital of Shanxi Medical University (SHSMU). Only the cases with prior HPV genotyping results in the preceding 6 months were included in the study and analyzed. Other clinical information, including age and clinical history were also collected. Histopathologic diagnoses were reported on samples including endocervical curettage specimens, cervical biopsies, loop electrosurgical excision procedures or cold-knife conization. The Second Hospital of Shanxi Medical University is a large, integrated, public health system located in the capital of Shanxi, which accommodates patients from all over Shanxi province.

HPV Geno-array test

HPV detection and genotyping was tested using HybriMax HPV Geno-Array kit (Hybribio Biotechnology Limited Corp., Chaozhou, China) at the Second Hospital of Shanxi Medical University laboratory. The HPV Geno-Array can determine 21 HPV genotypes, including 15 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, and 68) and 6 low risk HPV (lrHPV) types (6, 11, 41, 42, 44, and CP8304). Test was performed according to the manufacturer's instructions. Briefly, PCR was performed in a 25 μL reaction mixture containing 5 μL extracted DNA, 0.75 μL DNA Taq polymerase and 19.25 μL PCR-mix solution containing MY09/11 primer system. The PCR protocol was: denaturing at 95 °C for 9 min, followed by 40 cycles of 20s at 95 °C, 30s at 55 °C, and 30s at 72 °C, at last a finally extension at 72 °C for 5 min. A positive control and a negative control were run in each PCR analysis process to control for possible contamination and accuracy. The kit can simultaneously identify 21 HPV genotypes: adding NBT/BCIP solution to display the results, a positive result was indicated by a clearly visible indigo dot. The HPV-genotype result was determined by the position of the HPV-genotype probes on the microarray chip. Multiple dots indicated multiple infections.

Colposcopy and cervical histopathologic diagnosis

Colposcopy exams were performed by specialists according to a standardized protocol. During the exam, all visually abnormal areas were biopsied. The squamocolumnar junction was biopsied (“random biopsy”) if no visible lesion identified. Endocervical curettage (ECC) was then performed according to the aforementioned indications.

Statistical analysis

The Pearson chi-square test was used for statistical analysis, which was conducted with SAS 9.1 software (SAS Institute, Cary, North Carolina). A P value less than 0.05 was considered statistically significant.

Results

Overall HPV prevalence

A total of 1,387 CIN2/3 cases with HPV genotyping results within 6 months prior to histological diagnosis were included in the study. The overall hrHPV positive rate was 91.9% (1274/1387). The average time period from HPV testing to histological diagnosis was 0.4 months (range: 0.1-6 months) and the average age was 45.7 years (range: 21-83 years).

Distribution of single and multiple hrHPV infections

Single hrHPV infection was identified in 65.0% of all women (902/1,387), accounting for 71.0% (902/1,271) of hrHPV positive cases. Infection with multiple hrHPV types was identified in 26.6% of all women, accounting for 29.0% of hrHPV positive cases. Among the women infected with multiple hrHPV types, infection of two genotypes was most commonly observed with an overall prevalence rate of 17.5%. Infection with three and more hrHPV types were found in 99 women with an overall prevalence rate of 7.1% (Table 1).

hrHPV genotype distribution

The most commonly detected hrHPV genotype was HPV16 (59.3%), followed by HPV58 (14.4%) and HPV33 (10.0%), while HPV18 was in the 6th position (6.0%) (Table 2).
Table 1. 1387 cases with genotyping results 6 months before CIN2/3 diagnosis

| HPV infection   | Positive Case | %    |
|-----------------|---------------|------|
| HRHPV only      | 902           | 65.0 |
| 2 HRHPV only    | 244           | 17.5 |
| ≥3 HRHPV only   | 96            | 6.9  |
| Any mixed Hr and LrHPV | 32        | 2.3  |
| LrHPV only      | 10            | 0.7  |
| Negative (no both Hr and LrHPV) | 103  | 7.4  |
| Lr HPV          |               |      |
| Total           | 1387          | 100% |

Abbreviations: HRHPV, high-risk human papillomavirus; LRHPV, low-risk human papillomavirus number; CIN2/3, cervical intraepithelial neoplasia 2/3.

Table 2. HPV genotypes screening test results 6 months before CIN2/3 diagnosis (1387 cases)

| HPV type | Case No | Percentage |
|----------|---------|------------|
| 16       | 823     | 59.3       |
| 18       | 79      | 6.00       |
| 31       | 105     | 7.6        |
| 33       | 139     | 10.0       |
| 35       | 31      | 2.2        |
| 39       | 47      | 3.4        |
| 45       | 25      | 1.8        |
| 51       | 67      | 4.8        |
| 52       | 98      | 7.1        |
| 53       | 60      | 4.3        |
| 56       | 35      | 2.5        |
| 58       | 200     | 14.4       |
| 59       | 27      | 1.9        |
| 66       | 22      | 1.6        |
| 68       | 0       | 0.00       |
| LrHPV    |         |            |
| 11       | 23      | 1.7        |
| 42       | 12      | 0.9        |
| 81       | 14      | 1.0        |
| 6        | 7       | 0.5        |
| 41       | 3       | 0.2        |
| 44       | 4       | 0.3        |

Abbreviations: HRHPV, high-risk human papillomavirus; LRHPV, low-risk human papillomavirus number; CIN2/3, cervical intraepithelial neoplasia 2/3. No, number.

HrHPV infection among women of different Ages

All the 1,387 cases were divided into three age groups (<40 years, 40-49 years, and ≥50 years). The overall prevalence of hrHPV was 93.2% in women <40 years, 90.0% in women 40-49 years, and 92.2% in women ≥50 years. HrHPV positive rates showed no significant difference among these three age groups (p=0.1978). Additionally, the positive rates of HPV16 in the three groups were also similar and were 59.2% in women <40 years, 58.2% in women 40-49 years, and 60.6% in women ≥50 years respectively (p=0.7273).

Discussion

Epidemiological studies have suggested a substantial difference in the prevalence and genotype distribution of hrHPV infection among women from different countries. 16,17,18,19,20 Several large studies from China have demonstrated hrHPV prevalence rates in general population range from 9.9% to 21.1%. 9, 21, 22 However, studies of hrHPV infection in Chinese women with CIN2/3 were lacking. A study has reported that approximately 82.4% of cervical precancerous lesions and 92% of cervical invasive carcinoma are HPV-positive23. Zhao et al. reported that all 12 cases of cervical cancer and 31 cases of CIN3, and 95.3% of CIN2 (43 cases) were hrHPV positive.24 To our knowledge, the current study is one of the largest studies to investigate hrHPV prevalence in Chinese women with CIN2/3, demonstrating that 91.6% of these women were hrHPV positive.

In consistent with previous reports,25, 26 single HPV type infection is the most common infection in the current study, followed by the HPV infection with two types. Infection with 3 or more HPV types is rare. It remains exclusive whether HPV infection with multiple types is linked to occurrence or progression of cervical cancerous/precancerous lesions. One study suggested HPV infection with multiple types has increased risk for cervical cancerous/precancerous lesions27, while other studies did not show any increased risk for HPV infection with multiple types.28, 29 Further studies are still warranted to elucidate the role of infection with multiple HPV types in the development of cervical cancer.

HPV genotyping results for Chinese women with CIN2/3 are limited. The current study demonstrated the most commonly detected hrHPV genotype was HPV16 (59.3%), followed by HPV58 (14.4%) and HPV33 (10.0%), while HPV18 was only in the 6th position (6.0%). HPV16 was the predominant type among women with CIN2/3 in this study, consistent with previous studies from Western countries. 30, 31 However, the 2nd and 3rd most commonly detected types in current study were HPV58 and HPV33, which are different from the results observed in women from Western countries. 32, 33, 34, 35 HPV 16, HPV 33, and HPV 52 have been reported to be the most prevalent HPV types in Chinese women, however, the distribution of HPV genotype has been shown to be different from regions to regions in China. 9, 36, 37, 38 A study of 6723 subjects in four large cities (Beijing, Shanghai, Shenzhen, and Shenyang) and four rural areas (Shanxi: Xiangyu, Yangcheng, Henan Xinmi, and Xinjiang: Hotan) in China demonstrated HPV16 is the most common type, followed by HPV58 and HPV18. 39 However, all these results were derived from general Chinese population, none of the studies specifically investigated hrHPV genotyping in women with cervical precancerous/cancerous lesions. Our current study is the one of the largest to investigate hrHPV genotype distribution among women with CIN2/3, showing the top three most common types were
HPV16 (59.3%), HPV58 (14.4%) and HPV33 (10.0%), while HPV18 was in the 6th position (6.0%). A recent study indicated that the prevalence of HPV58 was 22.1% and 21.1% among HIV-1 positive women with CIN2 in Burkina Faso and South Africa respectively, and 23.1% and 15.1% among women with CIN3 and above lesions.  

In China, the development and application of HPV vaccines still face many challenges. Our study demonstrated that, even though HPV16 was the predominant type of HPV among Chinese women with CIN2/3, the following most common HPV types were not exactly the same as those found in other countries or regions. These data may provide a basis for formulating cervical cancer prevention strategies in China.

On April 24, 2014, the US Food and Drug Administration (FDA) approved a proposal by Roche Molecular Systems, (HPV) test as an alternate primary cervical cancer screening method for women aged 25 to 65 years. Current study showed 8% CIN2/3 patients had a negative HPV testing result before the histological diagnosis of high grade dysplasia, indicating the limitation of HPV testing as primary cervical cancer screening.

In summary, current study is the one of the largest case studies of HPV genotyping in Chinese women with histological diagnosis of CIN2/3. The knowledge of variable hrHPV genotypes in different countries and regions may be important for the development and application of HPV vaccines.  

Acknowledgements  
The study was supported by the grant from the Special Public Welfare Industry Research of National Health and Family Planning Commission (Beijing, China) 201402010.  

Competing Interests  
The authors have declared that no competing interest exists.

References
[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108.
[2] Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for sites in the adult population in 2008. Int J Cancer. 2011; 132:1-115.
[3] Shi JF, Qiao YL, Smith JS, et al. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia. Vaccine. 2008; 26 Suppl 12:S53-59.
[4] Wang X, Liu K, Yuan F, et al. Analysis of both high incidence of esophageal above lesions. J Cancer. 2016; 7(9):1037-43.
[5] Xie AY, Kremer AR, de Sanjose S. The beginning of the end: vaccine prevention of HPV-driven cancers. J Natl Cancer Inst. 2015; 107(6):dv128.
[6] Burchell AN, Winer RL, de Sanjose S, et al. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006; 24(53):52-61.
[7] Parkin DM, Fife KH, Cramer HM, et al. Multiple-type human papillomavirus infection and cervical cancer in Guangdong province, China: a population-based survey of 78,355 women. Sex Transm Dis. 2014; 41:732-738.
[8] Li C, Wu M, Wang J, et al. A population-based study on the risks of cervical lesion and human papillomavirus infection among women in Beijing. People's Republic of China. Cancer Epidemiol Biomarkers Prev. 2010; 19(5):1265-64.
[9] Cairenzhuoma, Zhang J, Wei C. Human papillomavirus infection in 26,622 women in Qinghai. Chin J Fam Plann. 2013; 21(12):812-816.
[10] Fernandes JV, Meissner RV, Carvalho MC, et al. Prevalence of human papillomavirus in archival samples obtained from patients with cervical pre-malignant and malignant lesions from Northeast Brazil. BMC Res Notes. 2010; 3(1):96.
[11] Zhao F, Li Na, Ma J, et al. Study of the association between human papillomavirus infection and cervical cancer in Xiangyan County, Shanxi province. Chin J Epidemiol. 2001; 22(5):375-378.
[12] Wang L, Li J, Chen L. Prevalence of human papillomavirus and its genotype among 1336 invasive cervical cancer patients in Hunan province, central south China. J Med Virol. 2015; 87:516-521.
[13] Dickson EL, Vogel RL, Bliss RL, et al. Multiple-type human papillomavirus (HPV) infections: across-sectional analysis of the prevalence of specific types in 409,000 women referred for HPV testing at the time of cervical cytology. J Med Virol. 2004; 74(4):550-559.
[14] Manoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-527.
[15] Langan RJ, Cho NH, Lee SY, et al. Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. Cancer. 2003; 97(7):1672-1680.
[16] Wright TC Jr, Stoler MH, Behrens CM, et al. Intraepithelial neoplasia in cervical conization specimens: what is the potential for prevention? Cancer Causes Control. 2014; 25(2):179-185.
[17] Peng Guan, Rebecca Howell-Jones, Ni Li, et al. Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int J Cancer. 2012; 131:2349-2359.
[18] Kim HJ. Human papillomaviruses. In: IARC, Humans WGotEoCRt. Biological Agents. Volume 100 B. A review of human carcinogens. IARC monographs on the evaluation of carcinogenic risks to humans / World Health Organization, International Agency for Research on Cancer 2012; 100:1-441.
[19] Wang X, Liu K, Yuan F, et al. Analysis of both high incidence of esophageal above lesions. J Cancer. 2016; 7(9):1037-43.
[20] Xu XX, Zhou JS, Yuan SH, et al. Distribution of HPV genotype in invasive cervical carcinoma and cervical intraepithelial neoplasia in Zhejiang Province, Southeast China: establishing the baseline for surveil lance. Int J Environ Res Public Health. 2015; 12(9):10794-10805.
[21] Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011; 128:927-935.
[22] Human papillomaviruses. In: IARC, Humans WGotEoCRt. Biological Agents. Volume 100 B. A review of human carcinogens. IARC monographs on the evaluation of carcinogenic risks to humans / World Health Organization, International Agency for Research on Cancer 2012; 100:1-441.
[23] Bruni L, Diaz M, Castellsague X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010; 202:1789-1799.
[24] Castellsague X, de Sanjose S, Aguado KS. WHO/ICO Information Centre on HPV and Cervical Cancer. HPV and cervical cancer in the 2007 report. Vaccine. 2007; 25 Suppl 3:C1-230.
[25] Jing L, Zhong X, Zhong Z, et al. Prevalence of human papillomavirus infection in Guangdong province, China: a population-based survey of 78,355 women. Sex Transm Dis. 2014; 41:732-738.
[26] Li C, Wu M, Wang J, et al. A population-based study on the risks of cervical lesion and human papillomavirus infection among women in Beijing. People's Republic of China. Cancer Epidemiol Biomarkers Prev. 2010; 19:2655-64.
[27] Cairenzhuoma, Zhang J, Wei C. Human papillomavirus infection in 26,622 women in Qinghai. Chin J Fam Plann. 2013; 21(12):812-816.
[28] Fernandes JV, Meissner RV, Carvalho MC, et al. Prevalence of human papillomavirus in archival samples obtained from patients with cervical pre-malignant and malignant lesions from Northeast Brazil. BMC Res Notes. 2010; 3(1):96.
[29] Zhao F, Li Na, Ma J, et al. Study of the association between human papillomavirus infection and cervical cancer in Xiangyan County, Shanxi province. Chin J Epidemiol. 2001; 22(5):375-378.
[30] Wang L, Li J, Chen L. Prevalence of human papillomavirus and its genotype among 1336 invasive cervical cancer patients in Hunan province, central south China. J Med Virol. 2015; 87:516-521.
[31] Dickson EL, Vogel RL, Bliss RL, et al. Multiple-type human papillomavirus (HPV) infections: across-sectional analysis of the prevalence of specific types in 409,000 women referred for HPV testing at the time of cervical cytology. J Med Virol. 2004; 74(4):550-559.
[32] Manoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-527.
[34] Castellsagué X, de Sanjosé S, Aguado KS, HPV WIICo, Cervical C: HPV and cervical cancer in the 2007 report. Vaccine 2007; 25 Suppl 3:C1-230.

[35] Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008; 26 Suppl10:K1-16.

[36] G M Clifford, S Gallus, R Herrero, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled Analysis. Lancet. 2005;366: 991–998.

[37] Ding X, Liu Z, Su J, et al. Human papillomavirus type-specific prevalence in women referred for colposcopic examination in Beijing. J Med Virol. 2014; 86:1937-43.

[38] Chih HJ, Lee AH, Colville L, et al. A review of dietary prevention of human papillomavirus-related infection of the cervix and cervical intraepithelial neoplasia. Nutr Cancer. 2013; 65(3):317-28.

[39] Zhao Y, Zhao F, Hu S, et al. Multi-center cross-sectional study on type-specific human papillomavirus infection among Chinese women. Chin J Epidemiol. 2015; 36(12):1351-1356.

[40] Kelly HA, Ngou J, Chikandiwa A, et al. Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa. PLoS One. 2017; 12(3):e0174117.